AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04488172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-vitamin supplementation
Description: Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day
Study NCT02099032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3g milk polar lipid fortified cheese consumption
Description: Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
Study NCT02099032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5g milk polar lipid fortified cheese consumption
Description: Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
Study NCT02099032 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified cheese product consumption
Description: Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
Study NCT01831492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeolite + dolomite
Description: Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
Study NCT01831492 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: given for 14 weeks
Study NCT00906503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
Study NCT00906503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/Computed Tomography (CT)
Description: Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
Study NCT00906503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose (18F)
Description: Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
Study NCT02800928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-501
Description: CERC-501
Study NCT02800928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03415490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Folded technique of self-adherent wrap
Description: Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once
Study NCT03415490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic technique of self-adherent wrap
Description: Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
Study NCT00618670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Three times per week for 3 months
Study NCT00618670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control--Resistance Training
Description: Three times per week for 3 months
Study NCT02244593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST MRI and mammography screening
Description: Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
Study NCT00482105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EGIR Tape
Description: Tape stripping is a non-invasive method that allows the recovery of cells
Study NCT04271592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H3733 Liquid Oral Dosage Form
Description: ABI-H3733 liquid oral dosage form
Study NCT04271592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H3733 Solid Oral Dosage Form
Description: ABI-H3733 solid oral dosage form
Study NCT04271592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ABI-H3733 Liquid Oral Dosage Form
Description: Placebo to ABI-H3733 liquid oral dosage form
Study NCT04271592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ABI-H3733 Solid Oral Dosage Form
Description: Placebo to ABI-H3733 solid oral dosage form
Study NCT01455376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperosmolar sodium lactate
Description: Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
Study NCT03896230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Product
Description: Three different doses of ketamine will be administered.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
Study NCT00107185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study NCT02945774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18F)-FEPPA
Description: PET ligand that binds to activated microglia, a marker of neuroinflammation
Study NCT01225042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
Study NCT01225042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo consisting of carrier material powder of identical appearance
Study NCT02096081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
Study NCT02096081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
Study NCT00421863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Norvasc 10 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study NCT03505359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial knee immobilization protocol
Description: 12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
Study NCT03505359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard ACL reconstruction rehabilitation protocol
Description: 12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
Study NCT02269618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home-based telehealth program
Description: Home-based telehealth program~* Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~* Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~* Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~* Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~* Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises.
Study NCT02269618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home-based rehabilitation
Description: Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~* Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~* Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg per day for a total of 40 weeks in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: 25mg/day for a total of 40 weeks in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin acetate
Description: One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: 3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuporelin acetate
Description: One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
Study NCT03272477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
Study NCT03272477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
Study NCT03272477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
Study NCT03272477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
Study NCT00421863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triatec 5 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study NCT03272477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
Study NCT01564654 — intervention group
Intervention type: DEVICE
Intervention: iTotal KRS
Description: Total Knee Replacement System
Study NCT00421863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pluscor
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study NCT01868243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Group 1 - Dabigatran 110 mg (50 patients)
Study NCT01868243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin adjusted-dose
Study NCT04406545 — intervention group
Intervention type: OTHER
Intervention: evaluation of skin microvascular flow and reactivity
Description: evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
Study NCT04190160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDegLira
Description: A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
Study NCT04511845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPYK04
Description: SPYK04 capsule
Study NCT03808714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TOUCHDOWN
Description: We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
Study NCT03808714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Alabama Quitline
Study NCT02270632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F8IL10
Description: F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
Study NCT02270632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
Study NCT02270632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
Study NCT02270632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
Study NCT03851744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sea Level
Description: Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
Study NCT03851744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Altitude
Description: Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
Study NCT01663740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
Study NCT00530712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROTÉGÉ® EverFlex™ Self-Expanding Stent System
Description: Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
Study NCT02573805 — intervention group
Intervention type: DEVICE
Intervention: Rigiscan test
Description: Rigiscan tests are performed in enrolled subjects for consecutive two nights.
Study NCT01795040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3/omega-6 fatty acids (PUFAs)
Description: Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
Study NCT01795040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-3/omega-6 fatty acids (PUFAs)
Description: Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
Study NCT02816762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
Study NCT02816762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
Study NCT02816762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
Study NCT02816762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Conventional anti-diabetic diet recommendations
Study NCT02816762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Conventional anti-diabetic diet recommendations
Study NCT00088010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arzoxifene
Description: 20mg, oral, tablet, once a day for 36 months
Study NCT00088010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, tablet, once a day for 36 months
Study NCT02269618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care All patients will be followed also in usual care manner by their GPs.
Study NCT00729118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Study NCT00729118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Study NCT02269618 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care All patients will be followed also in usual care manner by their GPs.
Study NCT03548545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
Study NCT03548545 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
Study NCT01861756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice decision aid
Description: The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.